Newborn affected by maternal cytotoxic drugs
ICD-10 P04.12 is a billable code used to indicate a diagnosis of newborn affected by maternal cytotoxic drugs.
Newborns affected by maternal cytotoxic drugs represent a significant concern in perinatal medicine. These drugs, which include chemotherapeutic agents and other noxious substances, can cross the placenta and affect fetal development, leading to a range of complications. Infants exposed to these substances may present with withdrawal symptoms, growth restrictions, and various organ dysfunctions. The effects can vary based on the timing of exposure during pregnancy, the type of drug, and the dosage. Common clinical manifestations include respiratory distress, feeding difficulties, and neurological impairments. Additionally, maternal use of substances such as alcohol, tobacco, and illicit drugs can further complicate the clinical picture, necessitating a comprehensive assessment and management plan for the affected newborn. Accurate coding is essential for tracking these cases and ensuring appropriate care and resources are allocated.
Detailed records of maternal drug use, newborn symptoms, and treatment plans.
Newborns in the NICU exhibiting withdrawal symptoms or requiring specialized care due to drug exposure.
Consideration of the timing of drug exposure and potential long-term effects on development.
Comprehensive pediatric assessments including developmental milestones and follow-up care plans.
Pediatric evaluations of children with histories of maternal drug exposure and associated complications.
Monitoring for developmental delays and behavioral issues stemming from prenatal exposure.
Used for newborns requiring evaluation and management due to maternal drug exposure.
Document maternal history, newborn assessment, and any interventions performed.
Neonatologists should ensure thorough documentation of the newborn's clinical status.
Common symptoms include respiratory distress, feeding difficulties, jitteriness, and withdrawal symptoms. Each case may vary based on the specific drug and timing of exposure.
